ArticleBMC genomic data2022

Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapy.

Adam Hermawan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.